Related Experiment Video
Updated: Aug 27, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.5K
Emerging systemic treatment options in meningioma
Maximilian J Mair1,2, Anna S Berghoff1,2, Priscilla K Brastianos3,4
1Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Journal of Neuro-Oncology
|October 1, 2022
Summary
Systemic therapy for meningioma is limited, but novel treatments targeting angiogenesis, genetic alterations, and immunotherapy show promise. Further research is needed to confirm these findings in large clinical trials.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Pharmacology
Background:
- Meningiomas are common intracranial tumors, typically treated with surgery or radiation.
- Evidence for pharmacotherapy in meningioma treatment is currently limited.
Purpose of the Study:
- To review the current landscape of systemic treatment options for meningioma.
- To explore emerging therapeutic targets and ongoing clinical trials for meningioma.
Main Methods:
- Literature screening of PubMed for systemic treatments in meningioma.
- Exploration of ongoing clinical trials using ClinicalTrials.gov.
Main Results:
- Traditional agents show limited efficacy; targeted therapies like tyrosine kinase inhibitors and monoclonal antibodies demonstrate potential.
- Investigational targets include mTOR, FAK, CDK, PI3K, sonic hedgehog, and histone deacetylases.
- Early trials of immune checkpoint inhibitors suggest meaningful responses in some patients.
Conclusions:
- High-level evidence for systemic meningioma treatment is scarce.
- Novel therapeutic targets and agents (anti-angiogenic, genomic, immunotherapy) show promise in early trials.
- Confirmation in large, prospective, controlled trials is necessary.
